Knight Therapeutics Inc. (TSX: GUD) announced that it has repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The company had drawn $60 million from the facility in June 2025 to help finance its acquisition of Paladin. The repayment was funded through strong cash flow generated by its operations in Canada and Latin America, demonstrating the company's financial discipline and operational strength.
The revolving credit facility continues to provide borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature available subject to certain conditions. This substantial undrawn capacity supports Knight's ongoing growth strategy across its pan-American pharmaceutical business. The repayment reduces interest expenses and strengthens the company's balance sheet, positioning it for future strategic initiatives.
Knight Therapeutics, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Its Latin American subsidiaries operate under United Medical, Biotoscana Farma, and Laboratorio LKM. The company's shares trade on the TSX under the symbol GUD. For more information, visit www.knighttx.com.
The full press release can be viewed at https://ibn.fm/8eluB.
